Guardant Health (GH) Cash & Equivalents (2017 - 2026)

Guardant Health has disclosed Cash & Equivalents across 10 years of filings, most recently posting $1.1 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 67.45% year-over-year to $1.1 billion; the TTM figure through Jun 2026 stood at $1.1 billion (up 67.45% YoY), while the FY2025 annual figure was $378.2 million, down 28.04% from the prior year.
• Cash & Equivalents came in at $1.1 billion for Q2 2026 at Guardant Health, up from $989.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.1 billion in Q4 2023 to a low of $141.6 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $587.6 million, with a median of $576.8 million recorded in 2022.
• Year-over-year, Cash & Equivalents sank 80.98% in 2022 and soared 700.25% in 2023.
• Over 5 years, Cash & Equivalents stood at $141.6 million in 2022, then jumped by 700.25% to $1.1 billion in 2023, then slumped by 53.64% to $525.5 million in 2024, then slipped by 28.04% to $378.2 million in 2025, then soared by 178.55% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.1 billion in Q2 2026, $989.3 million in Q1 2026, and $378.2 million in Q4 2025.